Tremfya: payments to doctors
Payments that named Tremfya as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $87.2M
- Providers
- 53,024
- Transactions
- 784,252
- Average per transaction
- $111
The per-transaction average — $111 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 53,024 providers the average total is $1,644, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Johnson & Johnson | $67,855,736 | 77.9% |
| Janssen Scientific Affairs, LLC | $17,942,057 | 20.6% |
| Janssen Research & Development, LLC | $848,153 | 1.0% |
| Janssen Global Services, LLC | $506,205 | 0.6% |
| Actelion Pharmaceuticals US, Inc. | $65 | 0.0% |
| Johnson & Johnson Vision Care, Inc. | $55 | 0.0% |